Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

Mayo Phase Consortium

Research output: Contribution to journalArticlepeer-review

118 Scopus citations

Fingerprint Dive into the research topics of 'Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds